Potentiators of defective DF508-CFTR gating that do not interfere with corrector action

Molecular Pharmacology

Volumn 88, Issue 4, 2015, Pages 791-799

  Phuan, Puay Wah ^a   Veit, Guido ^c   Tan, Joseph A ^a   Finkbeiner, Walter E ^b   Lukacs, Gergely L ^c   Verkman, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL) N [1 (2,3 DIHYDROXYPROPYL) 6 FLUORO 2 (2 HYDROXY 1,1 DIMETHYLETHYL) 1H INDOL 5 YL]CYCLOPROPANECARBOXAMIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENISTEIN; ISOXAZOLE DERIVATIVE; IVACAFTOR; LUMACAFTOR; PYRAZOLE; PYRROLE; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508;

ANIMAL CELL; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENTIATION; EC50; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN STABILITY; RAT; STRUCTURE ACTIVITY RELATION; WILD TYPE; AGONISTS; ANIMAL; CELL CULTURE; CELL LINE; CELL MEMBRANE; CHANNEL GATING; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; FISCHER 344 RAT; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AMINOPYRIDINES; ANIMALS; BENZODIOXOLES; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; HUMANS; ION CHANNEL GATING; RATS; RATS, INBRED F344; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84946402384     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.099689     Document Type: Article

References (33)

1. Ashlock MA and Olson ER (2011) Therapeutics development for cystic fibrosis: A successful model for a multisystem genetic disease. Annu Rev Med 62:107-125.
2. Boucher RC (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23:146-158.
3. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, and Rodman D; VX09-809-102 study group (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. Lancet Respir Med 2:527-538.
4. Chhabria M, Patel S, Dholakia S, Mistry H, and Patel S (2014) Synthesis and antitubercular activity of a series of thiazole derivatives. Anti-Infective Agents 12: 149-158.
5. Chhabria M, Rathod I, Vala K, and Patel P (2011) Identification of important structural features of thiazolo[4, 5-d]pyrimidines required for potent antifungal activity. Med Chem Res 20:1450-1454.
6. Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr, Das J, Dokholyan NV, Randell SH, Boucher RC, and Gentzsch M (2014) Potentiator ivacaftor abrogates pharmacological correction of DF508 CFTR in cystic fibrosis. Sci Transl Med 6:246-96.
7. Collins FS (1992) Cystic fibrosis: molecular biology and therapeutic implications. Science 256:774-779.
8. Davis PB (2006) Cystic fibrosis since 1938. Am J Respir Crit Care Med 173:475-482.
9. Davis PB, Yasothan U, and Kirkpatrick P (2012) Ivacaftor. Nat Rev Drug Discov 11: 349-350.
10. Ehrhardt C, Collnot EM, Baldes C, Becker U, Laue M, Kim KJ, and Lehr CM (2006) Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-. Cell Tissue Res 323: 405-415.
11. Fulcher ML and Randell SH (2013) Human nasal and tracheo-bronchial respiratory epithelial cell culture. Methods Mol Biol 945:109-121.
12. Galietta LJ, Haggie PM, and Verkman AS (2001) Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 499: 220-224.
13. Hanrahan JW, Sampson HM, and Thomas DY (2013) Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci 34:119-125.
14. Ito M, Suzaki T, Yamamoto S (2009) inventors, Ito M, Suzaki T, Takeda Pharmaceutical, Yamamoto S, assignee. Substituted pyrazole derivative. Patent WO2009028543 A1. 2009 Mar 5.
15. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJ, and Verkman AS (2002) High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 277:37235-37241.
16. Massari S, Nannetti G, Goracci L, Sancineto L, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, and Facchini M et al. (2013) Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. J Med Chem 56:10118-10131.
17. Naraian AS, et al. (2005) inventors, Pharmacia Corporation, assignee. Substituted pyrazoles as p38 kinase inhibitors. U.S. patent 6979686 B1. 2005 Dec 27.
18. Okiyoneda T, Barrière H, Bagdány M, Rabeh WM, Du K, Höhfeld J, Young JC, and Lukacs GL (2010) Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329:805-810.
19. O'Reilly R and Elphick HE (2013) Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. Drug Des Devel Ther 7:929-937.
20. Rowe SM and Verkman AS (2013) Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 3:a009761.
21. Patch RJ, Baumann CA, Liu J, Gibbs AC, Ott H, Lattanze J, and Player MR (2006) Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorg Med Chem Lett 16:3282-3286.
22. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, and Nantz MH et al. (2005) Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 67:1797-1807.
23. Phuan PW, Veit G, Tan J, Roldan A, Finkbeiner WE, Lukacs GL, and Verkman AS (2014) Synergy-based small-molecule screen using a human lung epithelial cell line yields DF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol 86:42-51.
24. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevínek P, Griese M, McKone EF, Wainwright CE, and Konstan MW et al.; VX08-770-102 Study Group (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663-1672.
25. Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77: 701-726.
26. van Amsterdam C, Arlt M, Bartoszyk G, Finsinger D, Schadt O, Schiemann K, Seyfried C (2004) inventors, Merck Patent Gmbh, assignee. Substituierte Pyrazolverbindungen. Patent DE10315569 A1. 2004 Oct 14.
27. Serohijos AW, Hegedus T, Aleksandrov AA, He L, Cui L, Dokholyan NV, and Riordan JR (2008) Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci USA 105:3256-3261.
28. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K, Bache KG, Papsin B, Zerangue N, and Stenmark H et al. (2004) Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 164:923-933.
29. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, and Hazlewood A et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106: 18825-18830.
30. Veit G, Avramescu RG, Perdomo D, Phuan PW, BagdanyM, Apaja PM, Borot F, Szollosi D, Wu YS, and Finkbeiner WE et al. (2014) Some gating potentiators, including VX-770, diminish DF508-CFTR functional expression. Sci Transl Med 6:246-97.
31. Veit G, Bossard F, Goepp J, Verkman AS, Galietta LJ, Hanrahan JW, and Lukacs GL (2012) Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Mol Biol Cell 23:4188-4202.
32. Yamaya M, Finkbeiner WE, Chun SY, and Widdicombe JH (1992) Differentiated structure and function of cultures from human tracheal epithelium. Am J Physiol 262:L713-L724.
33. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, and Pedemonte N et al. (2003) Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 278:35079-35085.